Nutraceutical Research Innovations Increases Zenagen Hair Loss Shampoo, Alopecia, and Hair Growth Products 2010 Outlook

Share Article

Increased World Wide Demand For New Zenagen Hair Loss Product Line Causes Company To Revise Outlook And Distribution For 2010. New Hair Loss Technology and Formulation Techniques Have Increased Industry Demand.

Past News Releases

RSS

Nutraceutical Research Innovations, LLC (NRI) announced increased production of the patent-pending Zenagen hair loss product line, due to increased world-wide demand the hair care products. The Miami based nutraceutical company introduced Zenagen hair loss shampoo at the International Beauty and Barber Show, Miami in August 2009. The company focuses on nutraceutical formulation and extraction process and developed the formulation for the patent-pending Zenagen hair care line of hair loss products.

The Zenagen hair loss line has rapidly expanded its distribution and international presence and has been expanding retail availability through exclusive distribution agreements.

The hair loss industry has experienced rapid development over the last 20 years with the introduction of blockbuster FDA approved products finasteride (Propecia) and Minoxidil (Rogaine). The billion dollar hair loss market has shown rapid growth. Hair loss affects over 80 million people in the US alone, with some studies showing the prevalence of mid-frontal hair loss increases with age and affects 57% of women and 73.5% of men aged 80 and over.

The most common cause of alopecia is known as androgenic alopecia, and is thought to be caused by the hormone dihydrotestosterone (DHT) a derivative of testosterone. DHT initiates a process of follicular miniaturization. Through the process of follicular miniaturization, hair shaft width is progressively decreased until scalp hair resembles fragile vellus hair or "peach fuzz" or else becomes non-existent.

NRI has recently expanded their focus of hair loss solutions including genetic research and gene therapy and expects to conclude a 3rd party phase 1 research study in early 2011.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website